NEW YORK, February 27, 2017 /PRNewswire/ --
Increased need for better cancer treatment continues to boost the global cancer biological therapy market. According to a
report published by Global Market Insights, cancer biological therapy market size is expected to reach USD
100 billion by 2023, at upwards of 6% growth from 2016 to 2023. Rising number of new cancer cases and mounting global
geriatric population are considered as two major factors that drive the demand for cancer therapies. Moreover, rising awareness
of the effectiveness of biological therapies also contributes to the expanding industry. Actinium Pharmaceuticals Inc. (NYSE:
ATNM), Agenus Inc. (NASDAQ: AGEN), Exelixis, Inc. (NASDAQ: EXEL), Array BioPharma (NASDAQ: ARRY), AstraZeneca Plc (NYSE: AZN)
According to the report, U.S. still dominates the North American cancer biological therapy market, accounting for over 80% of
the revenue in 2015. Increased public funding for R&D and other government initiatives are expected to drive growth in
the United States. In Europe, Germany is the largest player in the market due to increased prevalence and favorable public reimbursement
and insurance policies. While demand for biological therapy in the Asia Pacific is driving by
Japan and China.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a biopharmaceutical company developing innovative targeted
therapies for cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to
deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. lomab-B is Actinium's
lead product candidate that is currently being studied in a 150-patient, multicenter pivotal Phase 3 clinical trial in patients
with relapsed or refractory acute myeloid leukemia who are age 55 and above. Upon approval, Iomab-B is intended to prepare and
condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, which is often
considered the only potential cure for patients with certain blood-borne cancers and blood disorders.
In an interview with OncLive, Sergio A. Giralt, MD, chief of the Adult Bone Marrow Transplant
Service and the Melvin Berlin Family Chair in Multiple Myeloma at Memorial Sloan Kettering Cancer Center, commented on Iomab-B
and its potential, "New preparative regimens may allow for elimination of cells that could be potentially resistant to current
conditioning strategies, Giralt said. Adding targeted agents to the pretransplant conditioning regimen has the potential to
increase the antitumor effect. Options include gemtuzumab ozogamicin, an anti-CD33 monocloncal antibody; Iomab-B, a radiolabeled
antibody-drug conjugate targeted against CD45; and rituximab, an antibody directed against CD20."
Earlier on February 7 th Actinium Pharmaceuticals announced that a Phase 1 clinical
trial studying Actimab-M in multiple myeloma has been initiated. Actimab-M is comprised of the CD-33 targeting monoclonal
antibody HuM-195 coupled to the alpha-particle emitter actinium 225. CD33 is an antigen found on hematopoietic cells in certain
blood cancers. It is commonly associated with myeloid malignancies including AML, but recent research has shown that CD33 can
also be found on malignant cells of approximately 25%-35% of all multiple myeloma patients. Furthermore, the expression of this
marker increases in relapsed and refractory myeloma.
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and
cancer vaccines, announced recently a clinical trial collaboration with the National Cancer Institute (NCI). The double-blind,
randomized controlled Phase 2 trial will evaluate the effect of Agenus' personalized autologous vaccine candidate, Prophage™
(HSPPC-96), in conjunction with Merck's pembrolizumab on the overall survival rate of patients with newly diagnosed glioblastoma
(ndGBM). The trial will be conducted by the Brain Tumor Trials Collaborative (BTTC), a consortium of top academic centers led by
Dr. Mark Gilbert, Chief of the Neuro-Oncology Branch at the NCI Center for Cancer Research.
Exelixis, Inc. (NASDAQ: EXEL) and Takeda Pharmaceutical Company Limited today announced an exclusive licensing
agreement for the commercialization and further clinical development in Japan of cabozantinib,
Exelixis' lead oncology medicine. With the signing of the agreement, Takeda gains exclusive commercial rights for all potential
future cabozantinib indications in Japan. "As an organization with a strong focus on oncology
innovation, our agreement with Exelixis brings a promising and well-studied solid-tumor therapy to our pipeline that may help
patients in Japan suffering from RCC and potentially other equally devastating cancers," said
Tsudoi Miyoshi, Head of Japan Oncology Business Unit of Takeda.
Array BioPharma (NASDAQ: ARRY) and Pierre Fabre has jointly announced earlier in
November the new results from the pivotal Phase 3 COLUMBUS trial of binimetinib plus encorafenib (bini/enco) treatment in
BRAF-mutant melanoma patients at the Society for Melanoma Research Annual Congress. The study met its primary endpoint, with the
combination of bini/enco significantly improving progression free survival (PFS) compared with vemurafenib, a BRAF inhibitor,
alone. Melanoma is the fifth most common cancer among men and the seventh most common cancer among women in the United States, with more than 76,000 new cases and over 10,000 deaths from the disease expected in
2016.
AstraZeneca Plc (NYSE: AZN) has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new
medicines that have the potential to transform patients' lives and the Company's future. The company recently announced positive
results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician's choice of a
standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1
or BRCA2 mutations. Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in
progression-free survival (PFS) compared with those who received chemotherapy.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts
on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and
advertising for third parties for disseminating news and original content through our unique media platform that includes
Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
service agreements with the companies which are the subject to the articles posted on the Site or other editorials for
advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this
editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on
the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and
sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer
any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com
only regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has
been compensated a total of twelve thousand dollars for financial news dissemination and pr
services by a third party non affiliate for actinium pharmaceuticals inc. Our fees may be either a flat cash sum or negotiated
number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in
segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement.
FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising.
FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any
companies the information contained herein is not intended to be used as the basis for investment decisions and should not be
considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy,
hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from
the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own
independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By
accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended
from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase,
hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor.
This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular
security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and
tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions.
We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to
change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not
guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com